InsiderSignal.AI

InsiderSignal.ai

ARDX - Ardelyx, Inc.

Insider Sale by Raab Michael (Pres, CEO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

6 days ago, Raab Michael, serving as Pres, CEO at Ardelyx, Inc. (ARDX), sold 41,668 shares at $6.29 per share, for a total transaction value of $261,954.00. Following this transaction, Raab Michael now holds 1,820,978 shares of ARDX.

This sale represents a 2.00% decrease in Raab Michael's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Wednesday, April 15, 2026 and publicly disclosed via SEC Form 4 filing on Friday, April 17, 2026, 2 days after the trade was made.

Ardelyx, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Raab Michael

Raab Michael

Pres, CEO

Michael G. Raab is the President, Chief Executive Officer, and Director of Ardelyx, Inc. (ARDX), a biopharmaceutical company focused on innovative treatments, a role he has held since March 2009.[[1]](https://www.clay.com/dossier/ardelyx-ceo)[[2]](https://ardelyx.com/people/mike-raab-2/)[[8]](https://ardelyx.com/about-us/leadership/) Prior to Ardelyx, Raab was a partner at New Enterprise Associates (NEA), specializing in healthcare investments in biotechnology and pharmaceuticals from 2002 to 2008.[[2]](https://ardelyx.com/people/mike-raab-2/)[[3]](https://www.q1productions.com/mike-raab-ardelyx/) He spent 15 years in commercial and operating leadership roles, including as Senior Vice President of Therapeutics and General Manager of the Renal Division at Genzyme Corporation (now part of Sanofi), where he launched sevelamer (Renagel®), a leading phosphate binder exceeding $1 billion in worldwide sales, and therapies for Gaucher disease such as Ceredase and Cerezyme.[[2]](https://ardelyx.com/people/mike-raab-2/) Earlier positions include roles in business development, sales, and marketing at Repligen and Bristol-Myers.[[2]](https://ardelyx.com/people/mike-raab-2/) Raab holds a Bachelor of Arts from DePauw University.[[2]](https://ardelyx.com/people/mike-raab-2/)[[1]](https://www.clay.com/dossier/ardelyx-ceo) Beyond Ardelyx, he serves as Chairman of the Board at Amicus Therapeutics, Inc. (since March 2024), Tempest Therapeutics, Inc. (since 2019 or 2021), and holds directorships in organizations like the California Biomedical Innovation Alliance and Biotechnology Innovation Organization.[[4]](https://www.marketscreener.com/insider/MIKE-RAAB-A0AC59/)[[5]](https://amicusrx.com/about-us/leadership/michael-raab/) Under his leadership, Ardelyx has achieved milestones such as FDA approval of XPHOZAH and significant revenue growth.[[1]](https://www.clay.com/dossier/ardelyx-ceo)[[7]](https://fintool.com/app/research/companies/ARDX/people/michael-raab)

View full insider profile →

Trade Price

$6.29

Quantity

41,668

Total Value

$261,954.00

Shares Owned

1,820,978

Trade Date

Wednesday, April 15, 2026

6 days ago

SEC Filing Date

Friday, April 17, 2026

Filed 2 days after trade

HEALTHCAREBIOTECHNOLOGY

About Ardelyx, Inc.

Company Overview

No company information available
View news mentioning ARDX

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/5720462

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime